Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News 89Bio Inc ETNB

Healthcare Biotechnology
89bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. The Company’s lead product candidate, pegozafermin, a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is being developed for the treatment of metabolic dysfunction... see more

Recent & Breaking News (NDAQ:ETNB)

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire 9 days ago

89bio to Participate in Goldman Sachs 46th Annual Global Healthcare Conference

GlobeNewswire 11 days ago

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire May 9, 2025

89bio to Participate in Upcoming Investor Conferences

GlobeNewswire May 6, 2025

89bio Reports First Quarter 2025 Financial Results and Corporate Updates

GlobeNewswire May 1, 2025

89bio to Participate in the Leerink Partners Global Healthcare Conference

GlobeNewswire March 3, 2025

89bio Reports Fourth Quarter and Full Year 2024 Financial Results and Corporate Updates

GlobeNewswire February 27, 2025

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire February 6, 2025

89bio Announces Closing of its Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Shares

GlobeNewswire February 3, 2025

89bio, Inc. Announces Pricing of $250.0 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 28, 2025

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire January 27, 2025

89bio Provides Business Update and Outlook for 2025

GlobeNewswire January 13, 2025

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire December 19, 2024

89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire November 29, 2024

89bio to Participate in the 7th Annual Evercore HealthCONx Conference

GlobeNewswire November 26, 2024

89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests from the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting® 2024

GlobeNewswire November 15, 2024

89bio, Inc. Announces Upsized Pricing of $125.0 Million Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 12, 2024

89bio, Inc. Announces Proposed Underwritten Public Offering of Common Stock and Pre-Funded Warrants

GlobeNewswire November 12, 2024

89bio Reports Third Quarter 2024 Financial Results and Corporate Updates

GlobeNewswire November 7, 2024

89bio to Participate in the UBS Global Healthcare Conference

GlobeNewswire November 5, 2024